CA2647146A1 - Linear natriuretic peptide constructs - Google Patents

Linear natriuretic peptide constructs Download PDF

Info

Publication number
CA2647146A1
CA2647146A1 CA002647146A CA2647146A CA2647146A1 CA 2647146 A1 CA2647146 A1 CA 2647146A1 CA 002647146 A CA002647146 A CA 002647146A CA 2647146 A CA2647146 A CA 2647146A CA 2647146 A1 CA2647146 A1 CA 2647146A1
Authority
CA
Canada
Prior art keywords
amino acid
construct
alpha
ala
surrogate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002647146A
Other languages
English (en)
French (fr)
Inventor
Shubh D. Sharma
Margarita Bastos
Wei Yang
Hui-Zhi Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2647146A1 publication Critical patent/CA2647146A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002647146A 2006-03-30 2007-03-30 Linear natriuretic peptide constructs Abandoned CA2647146A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74396306P 2006-03-30 2006-03-30
US74396406P 2006-03-30 2006-03-30
US60/743,963 2006-03-30
US60/743,964 2006-03-30
PCT/US2007/065656 WO2007115182A2 (en) 2006-03-30 2007-03-30 Linear natriuretic peptide constructs

Publications (1)

Publication Number Publication Date
CA2647146A1 true CA2647146A1 (en) 2007-10-11

Family

ID=38564250

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002647146A Abandoned CA2647146A1 (en) 2006-03-30 2007-03-30 Linear natriuretic peptide constructs

Country Status (6)

Country Link
US (1) US7795221B2 (https=)
EP (1) EP2004633A4 (https=)
JP (1) JP2009532385A (https=)
AU (1) AU2007233123A1 (https=)
CA (1) CA2647146A1 (https=)
WO (1) WO2007115182A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964181B2 (en) 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
EP2004633A4 (en) 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
ATE539762T1 (de) * 2006-03-30 2012-01-15 Palatin Technologies Inc Aminosäureersatz für peptidkonstruktionen
IL186004A0 (en) * 2007-09-17 2008-01-20 Ariel University Res And Dev C Piperzine-based scaffolds for solid phase synthesis of combinatorial libraries and method for their preparation
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
WO2011038061A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
WO2013062900A1 (en) * 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) * 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US20140066367A1 (en) * 2012-08-31 2014-03-06 Mayo Foundation For Medical Education And Research Subcutaneous delivery of a long-acting natriuretic peptide
AU2015231110B2 (en) 2014-03-21 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
WO2015175502A2 (en) * 2014-05-12 2015-11-19 Palatin Technologies, Inc. Replacement therapy for natriuretic peptide deficiencies
CA3011294A1 (en) 2016-01-13 2017-07-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vascular extracellular matrix hydrogel
US11066469B2 (en) 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465158A (en) * 1891-12-15 Charles m
US4251438A (en) 1979-06-14 1981-02-17 The Upjohn Company Piperazinone and piperazine polypeptides
US4341698A (en) * 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4496544A (en) 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4952561A (en) 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides
JPS60184098A (ja) 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
US4618600A (en) 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
DE3588006T2 (de) 1984-04-19 1995-08-10 Scios Nova Inc Atrielle natriumuretische/gefässerweiterende polypeptide.
WO1985004872A1 (en) 1984-04-24 1985-11-07 The Salk Institute For Biological Studies Atrial peptide analogs
JPH0672155B2 (ja) 1984-08-24 1994-09-14 塩野義製薬株式会社 α−ｈＡＮＰ抗血清作製用ポリペプチド
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
FI872959A7 (fi) * 1985-11-05 1987-07-03 California Biotechnology Inc Natriureettisen vaikutuksen omaavien sydämen eteispeptidien analogeja .
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5057603A (en) 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
US4716147A (en) 1986-03-27 1987-12-29 Monsanto Company Synthetic airial peptides
EP0246795A3 (en) 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetic natriuretic peptides
US5159061A (en) 1986-09-29 1992-10-27 Takeda Chemical Industries, Ltd. Atrial natriuretic peptide derivative
US4804650A (en) 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
DK531986D0 (da) 1986-11-07 1986-11-07 Novo Industri As Peptider
WO1988006596A1 (en) 1987-03-02 1988-09-07 Bissendorf Peptide Gmbh New cardiodilatin fragment, process for preparing same and use thereof
US5095004A (en) 1987-03-25 1992-03-10 Bio-Mega Inc. Fluorine containing atrial natriuretic peptides
US5376635A (en) 1987-03-15 1994-12-27 Bio-Mega/Boehringer Ingelheim Research Inc. Fluorine containing atrial natriuretic peptides
US4816443A (en) 1987-05-19 1989-03-28 Merck & Co., Inc. Piptides having ANF activity
US5091366A (en) 1987-05-19 1992-02-25 Merck & Co., Inc. Peptides having ANF activity
IL86386A0 (en) 1987-05-21 1988-11-15 Merrell Dow Pharma Novel anf derivatives
JP2544929B2 (ja) 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
WO1989005654A1 (en) 1987-12-24 1989-06-29 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
US5047397A (en) * 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
WO1989010935A1 (en) 1988-05-09 1989-11-16 Abbott Laboratories Atrial peptide derivatives
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5057495A (en) 1988-06-24 1991-10-15 Queen's University At Kingston Atrial hypotensive peptide
DK380288D0 (da) 1988-07-07 1988-07-07 Novo Industri As Hidtil ukendet peptider
JP2848411B2 (ja) 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5106834A (en) * 1988-12-27 1992-04-21 G. D. Searle & Co. Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
DK0385476T4 (da) 1989-03-01 1999-12-20 Shionogi & Co Fysiologisk aktivt polypeptid og DNA
GR1001018B (el) 1989-05-24 1993-03-31 Abbott Lab Μεθοδος παρασκευης προδρομικων πεπτικων παραγωγων.
DE69032598T2 (de) 1989-06-23 1999-03-11 Genentech, Inc., South San Francisco, Calif. Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
CZ61893A3 (en) 1990-10-11 1994-01-19 Boehringer Ingelheim Kg Cyclopeptides, process of their preparation and their use as medicaments
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
JP2925391B2 (ja) 1992-01-09 1999-07-28 サントリー株式会社 Ａｒｄｓ治療用医薬組成物
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
DE69432123T2 (de) 1993-11-12 2004-01-08 Genentech, Inc., South San Francisco Rezeptor spezifische atrio-natriuretische peptide
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5567662A (en) 1994-02-15 1996-10-22 The Dow Chemical Company Method of making metallic carbide powders
FR2717484A1 (fr) 1994-03-16 1995-09-22 Pf Medicament Nouveaux composés pseudo-bis-peptidiques analogues de la CCK, leur procédé de préparation, leur utilisation à titre de médicament et les compositions pharmaceutiques les comprenant .
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE69733560T2 (de) 1996-03-04 2006-05-11 Scios Inc., Fremont TESTVERFAHREN UND REAGENZIEN ZUR QUANTIFIZIERUNG VON hBNP
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
JP4642946B2 (ja) 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
AU9487698A (en) 1997-09-11 1999-03-29 Music Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
WO2000018422A1 (fr) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
AU7352200A (en) 1999-09-01 2001-03-26 Regents Of The University Of California, The Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US20040077537A1 (en) 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
US20040063630A1 (en) 2002-03-18 2004-04-01 Scios, Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2006020841A2 (en) 2004-08-11 2006-02-23 Alza Corporation Apparatus and method for transdermal delivery of natriuretic peptides
EP2004633A4 (en) 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs

Also Published As

Publication number Publication date
EP2004633A2 (en) 2008-12-24
US7795221B2 (en) 2010-09-14
WO2007115182A3 (en) 2008-12-11
WO2007115182A2 (en) 2007-10-11
JP2009532385A (ja) 2009-09-10
EP2004633A4 (en) 2009-08-26
AU2007233123A1 (en) 2007-10-11
US20070232546A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
US7795221B2 (en) Linear natriuretic peptide constructs
ES2430323T3 (es) Construcciones de péptidos natriuréticos cíclicos
CN101505784B (zh) 环状利尿钠肽构建体
US7964181B2 (en) Amino acid surrogates for peptidic constructs
EP2004352B1 (en) Amino acid surrogates for peptidic constructs
US8580746B2 (en) Amide linkage cyclic natriuretic peptide constructs
US20170087205A1 (en) Replacement Therapy for Natriuretic Peptide Deficiencies
US20130274207A9 (en) Uses of Natriuretic Peptide Constructs
HK1134022B (en) Cyclic natriuretic peptide constructs

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20120330